Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate-loaded autologous erythrocyte-derived microparticles
- Development stage
- Unknown
- Lead developer
- Hui ting Xu
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
This investigational therapeutic approach consists of the chemotherapy agent **methotrexate** encapsulated within microparticles derived from the patient's own red blood cells (**autologous erythrocytes**). Developed by Dr. Hui ting Xu, this novel drug delivery system is designed for the localized treatment of **malignant ascites** secondary to gastric, colorectal, or ovarian cancers. By utilizing biological microparticles as a carrier, the therapy aims to achieve high local concentrations of methotrexate within the peritoneal cavity while potentially reducing systemic toxicity and improving the objective response rate compared to conventional intraperitoneal chemotherapy. It is administered via peritoneal perfusion, often in combination with systemic therapy.
- Other names
- Erythrocytes derived MPs containing MTXMTX-MPsAutologous erythrocytes derived microparticles packaging methotrexate
02
Targets
DHFR (Dihydrofolate reductase)DCK (Deoxycytidine kinase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on methotrexate-loaded autologous erythrocyte-derived microparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate-loaded autologous erythrocyte-derived microparticles.